National Institute on Drug Abuse (NIDA)

• NIDA recommends interested applicants reach out to their current program officer as listed on the Notice of Award for the most recent parent award to discuss whether a supplement request would be appropriate
• Administrative supplement requests above $99,999 in direct costs will be reviewed by the National Advisory Council on Drug Abuse.

NIDA accepts administrative supplement requests on a continuous basis but will consider them for funding four times a year; December, February, May and August. The final submission date for each fiscal year is July 1.

Chief Grants Management Officer
National Institute of Drug Abuse (NIDA)
Email: [email protected] 

• With few exceptions, NIDA funding for conference grants is usually ~ $10,000. 

• For applications requesting more than one year, the need for multiple years should be justified, e.g., the field develops rapidly enough to justify annual meetings or provide different areas of focus in future years.

NIDA Receipt and Referral Officer
[email protected]

• NIDA supports Individual Career Development Awards in all areas of research described in NIDAs current strategic plan.
• Prospective applicants are highly encouraged to contact a NIDA Program Official in their area of interest, prior to preparing an application by contacting [email protected].

• Salary Support: Up to $100,000 plus fringe benefits per year.

• Research Support: Up to $50,000 per year.

Office of Research Training and Career Development
National Institute on Drug Abuse (NIDA)
Email: [email protected]
 

• NIDA participates in all Ruth L. Kirschstein National Research Service Award (NRSA) Fellowships and the Predoctoral to Postdoctoral Transition Award.​ 
• NIDA supports fellowships in all areas of research described in NIDAs current strategic plan.
• Prospective applicants are highly encouraged to contact a NIDA Program Official in their area of interest, prior to preparing an application by contacting [email protected].

Current NRSA stipends, tuition/fees, and budgetary levels apply.

Office of Research Training and Career Development
National Institute on Drug Abuse (NIDA)
Email: [email protected]

• NIDA supports Institutional Career Development Awards in all areas of research described in NIDAs current strategic plan.
• Institutional training for clinician scholars is encouraged.
• Prospective applicants are highly encouraged to contact a NIDA Program Official in their area of interest, prior to preparing an application by contacting [email protected].

• Salary Support: Up to $100,000 plus fringe benefits per year.

• Research Support: Up to $50,000 per year

Office of Research Training and Career Development
National Institute on Drug Abuse (NIDA)
Email: [email protected]

• NIDA supports Institutional Training in all areas of research described in NIDAs current strategic plan.
• Prospective applicants are highly encouraged to contact a NIDA Program Official in their area of interest, prior to preparing an application by contacting [email protected].

• NIDA accepts T32 applications during every receipt date but funding decisions are made annually each spring for a July 1 start date.

• NIDA supports travel costs up to $2000 per trainee per year

Office of Research Training and Career Development
National Institute on Drug Abuse (NIDA)
Email: [email protected]

NIDA supported research education areas include, but are not limited to, the topics below:

• Summer Research Experiences: Supports institutions that provide high-quality research experiences for high school and college students and for science teachers during the summer academic break; summer research experiences must be in scientific research fields relevant to NIDA’s mission.
  • Clinical Research Experiences:  Supports research education activities for clinicians, clinicians in training, and clinical researchers that enhance the knowledge of substance use- and substance use disorder (SUD)-related research and provide opportunities for active participation in related research.
  • Research Education for Health Professionals: Supports programs designed to engage practicing health care professionals in education about current and emerging knowledge derived from scientific research on the neurobiology, epidemiology, prevention, and/or treatment of substance use disorders and related health conditions and provide strategies that can be applied during interactions with patients.
  • Courses, Curriculum and Methods: Supports programs that focus on one or more of the following: short courses for skill development, curriculum and methods for data science and other topics aligned with the NIDA mission
  • Public Health: Supports mentored substance use research training partnerships that embed public health trainees and early career public investigators within state and local health departments to conduct NIDA mission-relevant research and build the public health substance use research workforce.
  • Mentoring Activities: Supports programs focused on mentoring activities designed to enhance mentoring skills and prepare participants for NIDA mission-relevant careers in addiction science.
  • Other Research Education: Any other research education program that is aligned with NIDA’s mission can also be considered.

• Undergraduate
• Predoctoral
• Postdoctoral/Residency
• Early Career
• Established Investigator
• Other
  • High School
  • Clinicians and Clinical researchers
  • Medical/nursing/dental/pharmacy/other health profession students

Office of Research Training and Career Development
National Institute on Drug Abuse (NIDA)
Email: [email protected]
 

Consistent with NIH and Presidential priorities, the NIDA Small Business Program supports research and development of innovative medical and non-medical products and services for substance use disorders (SUDs) and adverse health consequences related to non-disordered drug use. Proposed solutions should improve access, affordability, and coordinated care across prevention, diagnosis, treatment, and recovery. NIDA prioritizes scalable solutions deployable within integrated delivery networks across healthcare, criminal justice, workforce, education, housing, and social service systems. Specific areas include, but are not limited to:

• Novel, mechanism-based treatments addressing the evolving overdose crisis (e.g., synthetic opioids, stimulants, polysubstance use)
• Best-in-class opioid use disorder treatments that improve retention and outcomes for individuals not adequately served by existing medications
• Innovative smoking cessation therapies that enhance adherence and long-term effectiveness
• First-in-class pharmacotherapeutics and medical devices for stimulant and cannabis use disorders
• Diagnostic tools for detection and quantification of drug exposure
• Medical devices, including digital diagnostics and therapeutics, and clinical decision support systems supporting SUDs and comorbid mental health conditions, with particular attention to pediatric populations.
• Digital health technologies addressing health-related social needs
• Human-biology-based new approach methodologies and other commercial research tools
• Forensic testing technologies identifying emerging drugs
• FDA Drug Development Tools and Medical Device Development Tools

NIDA strongly encourages applications that include early FDA engagement, consideration of regulatory pathways, payer engagement strategies, real-world evidence generation, and plans for sustainable adoption within integrated delivery networks and value-based care models.

A.    Drug Discovery and Development for SUD and medical consequences of drug use.

• Early discovery activities may range from target identification and validation through lead optimization to development of candidates.
• Assay development and validation.
• Preclinical and/or clinical drug development.
• New drug discovery and development-enabling technologies and tools, including Drug Development Tools (DDT), as defined by the FDA.

B.    FDA-regulated Medical Devices for SUD and medical consequences of drug use.

• New device development-enabling technologies and tools, including Medical Device Development Tools (MDDT), as defined by the FDA.
• Preclinical and clinical medical devices, including Software as Medical Device (SaMD).
   

Office of Translational Initiatives and Program Innovations (OTIPI)
[email protected]